Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: solid (48), dense (12), thick (51)

Recovering from a heart attack - patient information

Description: This booklet has been produced by the cardiac rehabilitation team to help you and your family understand more about your
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/Recovering-from-a-heart-attack-1363-PIL.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Ind
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Finance and Performance Reports 2023-24 Month 10 - January 2024

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2023-24 Month 10 10.3 Ian
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-10-January-2024.pdf

Finance and Performance Reports 2023-24 Month 6 September 2023

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 6 12.3 Ian Howard – Chief Financial
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-6-September-2023.pdf

Manual techniques - patient information

Description: This factsheet explains what manual techniques are and how they are performed.
Url: /Media/UHS-website-2019/Patientinformation/Respiratory/Manual-techniques-754-PIL.pdf

Papers Trust Board 28 March 2019

Description: Agenda Group Name: Date of Meeting: Venue: Time: Apologies to: Trust Board – Open Session 28 March 2019 Conference Room, Heart
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2019/Papers-Trust-Board-28-March-2019.pdf

Azacitidine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia AZACITIDINE (SC) - VENETOCLAX Regimen  AML – Azacitidine (SC) - Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AzacitidineSC-Venetoclax.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

Pazopanib v1.1

Description: Chemotherapy Protocol RENAL CELL PAZOPANIB Regimen Renal Cell - Pazopanib Indication First line treatment option for people with advanced renal cell carcinoma Second line treatme
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Pazopanib-v1.1.pdf

Ibrutinib (MCL) (560mg)

Description: Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Lymphoma with cyclin D1 overexpression or translocation breakpoints at t (11;14) • Failure to ac
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf

481 to 490 of 533

Previous … 47 48 49 50 51 … Next